 |
  |
|
|
|
 |
|
|
|
|
|
In clinical studies, the most frequent adverse event related to therapy with Lupron Depot-PED was an injection site reaction, seen in 5% of children in the combined studies. The recommended starting dose of Lupron Depot-PED is 0.3 mg/kg/4 weeks (minimum 7.5 mg). Inadequate dosing may result in poor control of the pubertal process, allowing continued sexual development; therefore, adherence to the 4-week dosing interval must be maintained. Stimulation of sexual development may occur after the first dose or if the dose is inadequate. Lupron Depot-PED is indicated in the treatment of children with central precocious puberty. Individual results may vary. Please see the full Prescribing Information and the Patient Product Information.
You will need Adobe® Reader® to view and print the prescribing information and patient product information. To download the free reader, click on the icon below.
All photos are of models and not of users of Lupron Depot-PED or persons suffering symptoms described.
